Erectile dysfunction: From biochemical pharmacology to advances in medical therapy

European Journal of Endocrinology

Volumn 143, Issue 2, 2000, Pages 143-154

  Maggi, M ^a   Filippi, S ^a   Ledda, F ^a   Magini, A ^a   Forti, G ^a  

^a Dept of Clinical Physiopathology ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC AMP; CYCLIC GMP; NITRIC OXIDE; PAPAVERINE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E1; SILDENAFIL; YOHIMBINE;

ADRENERGIC RECEPTOR BLOCKING; CORPUS CAVERNOSUM; DRUG INDICATION; DRUG MECHANISM; ENZYME INHIBITION; ERECTILE DYSFUNCTION; HUMAN; PENIS ERECTION; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE RELAXATION;

EID: 0033861491     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1430143     Document Type: Review

References (84)

1. Principles of the new sex therapy
2. Group treatment of premature ejaculation
3. Impotence
4. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle
5. A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle
6. Basal and acetylcholine-stimulated nitric oxide formation mediates relaxation of rabbit cavernous smooth muscle
7. Nitric oxide is a potent relaxant of human and rabbit corpus cavernosum
8. Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis
9. Localisation of nitric oxide synthase I, II and III in rat penile tissue
10. Nitric oxide relaxes rabbit corpus cavernosum smooth muscle via a potassium-conductive pathway
11. Studies on the mechanisms involved in the ATP-induced relaxation in human and rabbit corpus cavernosum
12. The potent relaxant effect of adenosine in rabbit corpora cavernosa is nitric oxide independent and mediated by A2 receptors
13. Multiple cyclic nucleotide phosphodiesterases
14. Sildenafil: A novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells
15. Long-term results with vacuum constriction device
16. Long-term results of arterial bypass surgery for impotence secondary to segmental vascular disease
17. Effect of nitric oxide-donor, linsidomine chlorhydrate, in treatment of human erectile dysfunction caused by venous leakage
18. Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction
19. Nitric oxide mediates penile erection in cats
20. A possible role for calcitonin-gene-related peptide in the regulation of the smooth muscle tone of the bladder and penis
21. Follow-up results of a combination of calcitonin gene-related peptide and prostaglandin E1 in the treatment of erectile dysfunction
22. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents
23. Adenosine: A new agent in the diagnosis of impotence
24. Functional adenosine receptors in human corpora cavernosa
25. Intracavernous injection of papaverine for erectile failure
26. Intracavernosal therapy
27. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction
28. Topical prostaglandin E1 SEPA gel for the treatment of erectile dysfunction
29. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for erection (MUSE) Study Group
30. MUSE therapy: Preliminary clinical observations
31. Sildenafil: A selective phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction
32. Effects of sildenafil citrate on human hemodynamics
33. Sildenafil, a novel effective oral therapy for male erectile dysfunction
34. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group
35. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease
36. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies
37. Overall cardiovascular profile of sildenafil citrate
38. Sildenafil citrate and blood-pressure-lowering drugs: Results of drug interaction studies with an organic nitrate and a calcium antagonist
39. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue
40. Cardiovascular effects of sildenafil citrate and recommendations for its use
41. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association
42. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment
43. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial. Sildenafil Diabetes Study Group
44. Adrenergic alpha-receptors outnumber beta-receptors in human penile corpus cavernosum
45. Identification of alphal-adrenergic receptor subtype in human corpus cavernosum tissue and in cultured trabecular smooth muscle cells
46. Expression of functional alpha2-adrenergic receptor subtypes in human corpus cavernosum and in cultured trabecular smooth muscle cells
47. Physiology of penile erection
48. Comparison of the responses to drugs acting on adrenoceptors and muscarinic receptors in human isolated corpus cavernosum and cavernous artery
49. The expression of functional postsynaptic α2-adrenoceptors in the corpus cavernosum smooth muscle
50. Adrenoceptor-mediated regulation of the contractility in horse penile resistance arteries
51. Prejunctional alpha 2-adrenoceptors inhibit nitrergic neurotransmission in horse penile resistance arteries
52. Are the effects of androgens on male sexuality noradrenergically mediated? Some consideration of the human
53. Alpha receptors in the central nervous system and its effects on erection
54. Evidence for the modulation of sexual behavior by alpha-adrenoceptors in male rats
55. Alpha-adrenergic receptors in the penis: Identification, characterization, and physiological function
56. Role of alpha1-adrenoceptors in the future treatment of urological diseases
57. Cavernosal alpha-blockade: A new technique for investigating and treating erectile impotence
58. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence
59. The differential effects of prostaglandin E1 and nitroglycerin on regional cerebral oxygenation
60. Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents
61. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction
62. Effect of large doses of the nitric oxide precursor, L-arginine, on erectile dysfunction
63. Pharmacological therapy of erectile dysfunction
64. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension study
65. Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction
66. Outcomes of varicocele ligation done for pain
67. 3H]RS79948-197 binding to human, rat, guinea pig and pig alpha2A-, alpha2B- and alpha2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine
68. Enhancement of sexual motivation in male rats by yohimbine
69. Opioid antagonists and the sexual satiation phenomenon
70. Alpha2-adrenoceptor antagonists evoke endothelium-dependent and -independent relaxations in the isolated rat aorta
71. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial
72. Double blind trial of yohimbine in treatment of psychogenic impotence
73. Effect of yohimbine hydrochloride on erectile impotence: A double blind study
74. Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy
75. The role of yohimbine for the treatment of erectile impotence
76. Effects of yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction
77. Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction
78. Therapeutics effects of high dose yohimbine hydrochloride on organic erectile dysfunction
79. Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials
80. Yohimbine elimination in normal volunteers is characterized by both one- and two-compartment behavior
81. Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and non-obese women
82. Pharmacokinetic study of yohimbine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic antidepressants
83. Fifteen years experience of penile prothesis insertion